Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.

Genes - 9 Oct 2021

Tang Yun-Hsin, Lin Chiao-Yun, Lai Chyong-Huey

Abstract excerpt

With the advent of next-generation sequencing (NGS), The Cancer Genome Atlas (TCGA) research network has given gynecologic cancers molecular classifications, which impacts clinical practice more and more. New cancer treatments that identify and target pathogenic abnormalities of genes have been in rapid development. The most prominent progress in gynecologic cancers is the clinical efficacy of poly(ADP-ribose)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genital Neoplasms, Female
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34680987
DOI: 10.3390/genes12101593
PMCID: PMC8535522

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.PMID 34680987Read ↗

Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

Genomic insights in gynecologic cancer.Semantic proximity Read ↗

Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.Semantic proximity Read ↗

PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?Semantic proximity Read ↗

Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell LinesSemantic proximity Read ↗

Role of Genetics in Gynecologic Malignancies.Semantic proximity Read ↗

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.Semantic proximity Read ↗

Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancerSemantic proximity Read ↗

Molecular Pathogenesis Early Detection Strategies and Precision Therapeutic Advances in Ovarian CancerSemantic proximity Read ↗

Biology-driven therapy advances in high-grade serous ovarian cancerSemantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.